Assessing the therapeutic potential of long-chain isomaltooligosaccharides in diabetic and hyperlipidemic rats

Journal article

Authors/Editors

RATTIYA WAEONUKUL

Strategic Research Themes

food for the future (Sustainable Bioeconomy)

Publication Details

Author list: Onrapak Reamtong, Rattiya Waeonukul, Pattaneeya Prangthip

Publisher: BMC (part of Springer Nature) / BioMed Central

Publication year: 2024

Journal: BMC Systems Biology (1752-0509)

Volume number: 16

Issue number: 1

ISSN: 1752-0509

URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85198717581&doi=10.1186%2fs13098-024-01374-0&partnerID=40&md5=0ae89181e9223f31e9ccbc49f858bf5b

Languages: English-Great Britain (EN-GB)

View on publisher site

Abstract

Background: The global rise in diabetes prevalence necessitates effective treatments. Rats, mimicking physiological changes seen in Type 2 diabetes, serve as valuable models for studying metabolic disorders. Natural health supplements, especially prebiotics, are gaining interest for improving metabolic health. Isomaltooligosaccharides (IMOs), classified as functional oligosaccharides and prebiotics, have attracted attention due to their beneficial effects on gut microbiota balance and cholesterol reduction. However, commercial IMOs often contain undesirable sugars, leading to the development of long-chain IMOs with enhanced prebiotic properties. Methods: This study assessed the therapeutic potential of long-chain IMOs derived from Bacillus subtilis strain AP-1 compared to inulin, a widely recognized prebiotic, in addressing hyperglycemia and hyperlipidemia in rats. Results: IMOs treatment effectively reduced blood sugar and triglyceride levels similarly to inulin supplementation. Proteomic analysis revealed changes in hepatic protein profiles, with upregulated pathways including glutathione metabolism, oxidative phosphorylation, and pentose and glucuronate interconversion, while pathways related to fatty acid and amino acid biosynthesis exhibited downregulation. These results suggest promising therapeutic effects of IMOs treatment on diabetes and hyperlipidemia by influencing key metabolic pathways. Conclusions: Our findings highlight the potential of long-chain IMOs as targeted interventions for metabolic disorders, warranting further investigation into their clinical applicability and mechanisms of action. © The Author(s) 2024.

Keywords

Bacillus subtilis strain AP-1, Diabetes, Isomaltooligosaccharides